Cervavac is a quadrivalent human papillomavirus (HPV) vaccine developed by the Serum Institute of India. It is India's first indigenously produced vaccine
Cervavac protects against four types of HPV:
HPV 6 and 11: Cause approximately 90% of genital warts.
HPV 16 and 18: Cause approximately 70% of cervical cancers.
Cervavac is currently approved for girls and women 9 to 26 years old.
Cervavac is given as a series of two or three injections, depending on age:
9-14 years old: Two doses, 6 months apart.
15-26 years old: Three doses, 0, 2, and 6 months apart.
Studies suggest Cervavac is highly effective in preventing HPV infection and cervical cancer caused by the four targeted types.
Safety:
Cervavac is generally considered safe and well-tolerated.
Common side effects include pain at the injection site, headache, fever, and muscle aches.
COMMENTS